{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:23:30Z","timestamp":1776803010870,"version":"3.51.2"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Heart & Stroke Foundation of Ontario (HSFO)","award":["NA7187"],"award-info":[{"award-number":["NA7187"]}]},{"name":"NSERC Discovery","award":["RGPIN 238547-2009"],"award-info":[{"award-number":["RGPIN 238547-2009"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ejmech.2015.01.022","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T02:36:40Z","timestamp":1421030200000},"page":"890-907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153\u2013421): Design, synthesis and biochemical evaluation"],"prefix":"10.1016","volume":"92","author":[{"given":"Rasha H.","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-5984","authenticated-orcid":false,"given":"James","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Lagace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8092-2862","authenticated-orcid":false,"given":"Ajoy","family":"Basak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2015.01.022_bib1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2015.01.022_bib2","series-title":"Proprotein Convertases, Springer Protocols","first-page":"367","year":"2011"},{"issue":"30","key":"10.1016\/j.ejmech.2015.01.022_bib3","doi-asserted-by":"crossref","first-page":"21473","DOI":"10.1074\/jbc.R113.481549","article-title":"The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions","volume":"288","author":"Seidah","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2015.01.022_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"26","key":"10.1016\/j.ejmech.2015.01.022_bib5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMra1106700","article-title":"Proprotein convertases in health and disease","volume":"365","author":"Artenstein","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2015.01.022_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/1389202911314050010","article-title":"Genetics of the first seven proprotein convertase enzymes in health and disease","volume":"14","author":"Turpeinen","year":"2013","journal-title":"Curr. Genomics"},{"issue":"5","key":"10.1016\/j.ejmech.2015.01.022_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1515\/BMC.2011.034","article-title":"On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications","volume":"2","author":"Couture","year":"2011","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.ejmech.2015.01.022_bib8","first-page":"773","article-title":"On the discovery of precursor processing","volume":"768","author":"Steiner","year":"2011","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2015.01.022_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2009.02.012","article-title":"Cellular and secreted pro-protein convertase subtilisin\/kexin type 9 catalytic activity in hepatocytes","volume":"206","author":"Kourimate","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ejmech.2015.01.022_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2015.01.022_bib11","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2015.01.022_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070664","article-title":"Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity","volume":"406","author":"Li","year":"2007","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.ejmech.2015.01.022_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/bi7016359","article-title":"Self-association of human PCSK9 correlates with its LDLR-degrading activity","volume":"47","author":"Fan","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2015.01.022_bib14","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ejmech.2015.01.022_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14728220802600715","article-title":"PCSK9 as a therapeutic target of dyslipidemia","volume":"13","author":"Seidah","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"issue":"5","key":"10.1016\/j.ejmech.2015.01.022_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwh237","article-title":"Familial hypercholesterolemia and coronary heart disease: a HuGE association review","volume":"160","author":"Ausin","year":"2004","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.ejmech.2015.01.022_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ejmech.2015.01.022_bib18","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9 in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2015.01.022_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"issue":"2","key":"10.1016\/j.ejmech.2015.01.022_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.ejmech.2015.01.022_bib21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/jmg.2008.059980","article-title":"A\u00a0PCSK9 variant and familial combined hyperlipidemia","volume":"45","author":"Abifadel","year":"2008","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.ejmech.2015.01.022_bib22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2015.01.022_bib23","doi-asserted-by":"crossref","first-page":"33745","DOI":"10.1074\/jbc.M112.399725","article-title":"Loss- and gain-of-function PCSK9 variants cleavage specificity, dominant negative effects, and low density lipoprotein receptor (ldlr) degradation","volume":"287","author":"Benjannet","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"issue":"47","key":"10.1016\/j.ejmech.2015.01.022_bib24","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants","volume":"279","author":"Benjannet","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2015.01.022_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1476-511X-12-70","article-title":"Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations","volume":"12","author":"Mayne","year":"2013","journal-title":"Lipids Health Dis."},{"issue":"9","key":"10.1016\/j.ejmech.2015.01.022_bib26","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/hmg\/ddl077","article-title":"Effect of mutations in the PCSK9 gene on the cell surface LDL receptors","volume":"15","author":"Caneron","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.ejmech.2015.01.022_bib27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","article-title":"Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture","volume":"57","author":"Mayne","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejmech.2015.01.022_bib28","article-title":"Proprotein convertase Subtilisin\/Kexin 9 inhibitors: an emerging lipid-lowering therapy?","author":"Dragan","year":"2014","journal-title":"J.\u00a0Cardiovasc. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2015.01.022_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MCA.0000000000000113","article-title":"Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia","volume":"25","author":"Stawowy","year":"2014","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.ejmech.2015.01.022_bib30","first-page":"601","article-title":"Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses","volume":"16","author":"Briel","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"issue":"5","key":"10.1016\/j.ejmech.2015.01.022_bib31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/138161209787315684","article-title":"Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy","volume":"15","author":"Zhou","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.ejmech.2015.01.022_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jtcvs.2009.03.054","article-title":"Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review","volume":"138","author":"Liakopoulos","year":"2008","journal-title":"J.\u00a0Thorac. Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.ejmech.2015.01.022_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharmthera.2009.01.002","article-title":"Statins and cardioprotection\u2013more than just lipid lowering","volume":"122","author":"Ludman","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2015.01.022_bib34","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ejmech.2015.01.022_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2015.01.022_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: a meta-analysis","volume":"28","author":"Silva","year":"2006","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2015.01.022_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1538574410362922","article-title":"Basic science review: statin therapy\u2013part I: the pleiotropic effects of statins in cardiovascular disease","volume":"44","author":"Sadowitz","year":"2010","journal-title":"Vasc. Endovasc. Surg."},{"issue":"9732","key":"10.1016\/j.ejmech.2015.01.022_bib38","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/S0140-6736(10)60988-9","article-title":"Statins and risk of incident diabetes","volume":"375","author":"Eisenberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2015.01.022_bib39","article-title":"Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials","author":"Zhang","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2015.01.022_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pharmthera.2010.03.007","article-title":"Perspectives of the non-statin hypolipidemic agents","volume":"127","author":"Rozman","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2015.01.022_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1358\/dnp.2008.21.6.1246795","article-title":"Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia","volume":"21","author":"Lopez","year":"2008","journal-title":"Drug News Perspect."},{"issue":"24","key":"10.1016\/j.ejmech.2015.01.022_bib42","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1073\/pnas.0904560106","article-title":"Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels","volume":"106","author":"Steinberg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.ejmech.2015.01.022_bib43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"issue":"33","key":"10.1016\/j.ejmech.2015.01.022_bib44","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Racie TS and 27 co-authors. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"24","key":"10.1016\/j.ejmech.2015.01.022_bib45","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A\u00a0proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.ejmech.2015.01.022_bib46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","article-title":"Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor","volume":"419","author":"Duff","year":"2009","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.ejmech.2015.01.022_bib47","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ejmech.2015.01.022_bib48","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2015.01.022_bib49","unstructured":"ClinicalTrialsgov. The Evaluation of PF-04950615 (RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01975389?term=SPIRE-2&rank=1, Published March 4, 2014, (accessed 19.03.14.)."},{"key":"10.1016\/j.ejmech.2015.01.022_bib50","unstructured":"Mason I. PharmaTimes on line, Antibody lipid treatments enter final furlong, www.pharmatimes.com\/article\/13-09 02\/Antibody_lipid_treatments_enter_final_furlong.aspx."},{"key":"10.1016\/j.ejmech.2015.01.022_bib51","first-page":"1","article-title":"Lipid lowering with PCSK9 inhibitors","author":"Dadu","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"issue":"7","key":"10.1016\/j.ejmech.2015.01.022_bib52","first-page":"271","article-title":"Hyperlipidemia. New treatment option with Evolocumab","volume":"37","author":"Ecker-Schlipf","year":"2014","journal-title":"Med. Monatsschr. Pharm."},{"issue":"1","key":"10.1016\/j.ejmech.2015.01.022_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A\u00a0PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in\u00a0vivo","volume":"52","author":"Ni","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"issue":"2","key":"10.1016\/j.ejmech.2015.01.022_bib54","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.chembiol.2013.11.014","article-title":"Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in\u00a0vitro","volume":"21","author":"Schroeder","year":"2014","journal-title":"Chem. Biol."},{"issue":"46","key":"10.1016\/j.ejmech.2015.01.022_bib55","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1074\/jbc.M805971200","article-title":"Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels","volume":"283","author":"Mayer","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2015.01.022_bib56","doi-asserted-by":"crossref","first-page":"e41865","DOI":"10.1371\/journal.pone.0041865","article-title":"Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation","volume":"7","author":"Seidah","year":"2012","journal-title":"PLoS ONE"},{"issue":"20","key":"10.1016\/j.ejmech.2015.01.022_bib57","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2174\/092986710791299948","article-title":"Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin\/Kexin 9 (PCSK9) on LDL-R","volume":"17","author":"Palmer Smith","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2015.01.022_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"issue":"24","key":"10.1016\/j.ejmech.2015.01.022_bib59","first-page":"1","article-title":"Therapeutic potential of moringa oleifera leaves in chronic hyperglycemia and dyslipidemia: a review","volume":"3","author":"Mbikay","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2015.01.022_bib60","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2015.01.022_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.ejmech.2015.01.022_bib62","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4254\/wjh.v5.i12.676","article-title":"New compounds able to control hepatic cholesterol metabolism: is it possible to avoid statin treatment in aged people?","volume":"5","author":"Trapani","year":"2013","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejmech.2015.01.022_bib63","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"issue":"37","key":"10.1016\/j.ejmech.2015.01.022_bib64","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.0703402104","article-title":"The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain","volume":"104","author":"Hampton","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.ejmech.2015.01.022_bib65","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1074\/jbc.M110.199042","article-title":"A\u00a0two-step binding model of PCSK9 interaction with the low density lipoprotein receptor","volume":"288","author":"Yamamoto","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2015.01.022_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6064\/2012\/927352","article-title":"Proprotein convertase subtilisin\/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases","author":"Ferri","year":"2012","journal-title":"Scientifica"},{"key":"10.1016\/j.ejmech.2015.01.022_bib67","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.M808363200","article-title":"Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants","volume":"284","author":"Bottomley","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2015.01.022_bib68","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2174\/156652412802480961","article-title":"In\u00a0vitro regulatory effects of epidydimal serpin CRES on protease activity of proprotein convertase 4 (PC4)","volume":"12","author":"Mishra","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejmech.2015.01.022_bib69","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.3390\/molecules18055155","article-title":"Understanding acid lability of cysteine protecting groups","volume":"18","author":"Tomillero","year":"2013","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ejmech.2015.01.022_bib70","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10989-008-9148-x","article-title":"Group removal quenching of iodine and isolation of peptide by one step ether precipitation","volume":"14","author":"Zhang","year":"2008","journal-title":"Int J. Peptide Res. Ther."},{"key":"10.1016\/j.ejmech.2015.01.022_bib71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/cc7001588","article-title":"Cysteine-S-trityl a key derivative to prepare N-methyl cysteines","volume":"10","author":"Marcucci","year":"2008","journal-title":"J.\u00a0Comb. Chem."},{"key":"10.1016\/j.ejmech.2015.01.022_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/S1080-8914(96)80030-5","article-title":"Formation of a Disulfide Bond in an Octreotide-like Peptide: a Multicenter Study","author":"Angeletti","year":"1996"},{"key":"10.1016\/j.ejmech.2015.01.022_bib73","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.82.21.7160","article-title":"Tyrosine sulfation of proteins from the human hepatoma cell line HepG2","volume":"82","author":"Liu","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2015.01.022_bib74","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/abio.1996.0171","article-title":"Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies","volume":"236","author":"Zor","year":"1996","journal-title":"Anal. Biochem."},{"issue":"12","key":"10.1016\/j.ejmech.2015.01.022_bib75","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"Kosenko","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2015.01.022_bib76","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1194\/jlr.M044156","article-title":"Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts","volume":"55","author":"Nguyen","year":"2014","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2015.01.022_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cbic.200700007","article-title":"A\u00a0fluorogenic peptide containing the processing site of human SARS corona virus S-protein kinetic evaluation and NMR structure elucidation","volume":"8","author":"Basak","year":"2007","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ejmech.2015.01.022_bib78","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-61779-080-5_20","article-title":"Cell sensitivity assays: the MTT assay","volume":"731","author":"van Meerloo","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2015.01.022_bib79","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1016\/j.febslet.2005.07.062","article-title":"Modulating furin activity with designed mini-PDX peptides: synthesis and in\u00a0vitro kinetic evaluation","volume":"579","author":"Basak","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2015.01.022_bib80","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1039\/b000963f","article-title":"Nitrogen substituted cyclic azaenediynes: synthesis, thermal reactivity and complexation with metal ions","volume":"1","author":"Basak","year":"2000","journal-title":"J. Chem. Soc. Perkin Trans."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2015.01.022_bib81","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.molstruc.2011.05.023","article-title":"Fluorescence quenching and ligand binding: a critical discussion of a popular methodology","volume":"998","author":"van de Weert","year":"2011","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.ejmech.2015.01.022_bib82","unstructured":"Matrices Probes Hand book, Avidin, Streptavidin, NeutrAvidin and CaptAvidin Biotin-Binding Proteins and Affinity, Section 7.6."},{"issue":"31","key":"10.1016\/j.ejmech.2015.01.022_bib83","doi-asserted-by":"crossref","first-page":"17193","DOI":"10.1021\/jp503670a","article-title":"Sensing reversible protein-ligand interactions with single-walled carbon nanotube field-effect transistors","volume":"118","author":"M\u00fcnzer","year":"2014","journal-title":"J.\u00a0Phys. Chem. C. Nanomater Interfaces"},{"issue":"4","key":"10.1016\/j.ejmech.2015.01.022_bib84","first-page":"199","article-title":"The structural effect of the E148Q MEFV mutation on the pyrin protein: a study using a quantum chemistry model","volume":"13","author":"Naimushin","year":"2011","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.ejmech.2015.01.022_bib85","doi-asserted-by":"crossref","first-page":"570","DOI":"10.7326\/0003-4819-56-4-570","article-title":"Effect of dextro-isomers of thyroid hormones on serum cholesterol levels in euthyroid hypercholesterolemic patients","volume":"56","author":"Hollister","year":"1962","journal-title":"Ann. Int. Med."},{"issue":"28","key":"10.1016\/j.ejmech.2015.01.022_bib86","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.2174\/138161210793292555","article-title":"Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization","volume":"16","author":"Gentilucci","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"10.1016\/j.ejmech.2015.01.022_bib87","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/17460441.2012.712513","article-title":"The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors","volume":"7","author":"Hamada","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2015.01.022_bib88","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.saa.2013.09.105","article-title":"Pseudo-peptides as novel antileptospiral agents: synthesis and spectral characterization","volume":"118","author":"Shivamallu","year":"2014","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ejmech.2015.01.022_bib89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CRD.0000000000000014","article-title":"Antihyperlipidemic therapies targeting PCSK9","author":"Weinreich","year":"2014","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ejmech.2015.01.022_bib90","first-page":"14","article-title":"Established and emerging approaches for the management of dyslipidaemia","author":"Norata","year":"2012","journal-title":"Scientifica"},{"issue":"103","key":"10.1016\/j.ejmech.2015.01.022_bib91","first-page":"1","article-title":"Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats","volume":"12","author":"Jia","year":"2014","journal-title":"J.\u00a0Transl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2015.01.022_bib92","first-page":"1","article-title":"A\u00a0review on commercial, traditional uses, phytoconstituents and pharmacological activity of Moringa Oleifera","volume":"2","author":"Wadhwa","year":"2013","journal-title":"Glob. J. Trad. Med. Sys."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523415000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523415000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T06:55:52Z","timestamp":1537944952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523415000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":92,"alternative-id":["S0223523415000422"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2015.01.022","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153\u2013421): Design, synthesis and biochemical evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2015.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}